• It Pays to be Thin

  • Aug 1 2024
  • Length: 46 mins
  • Podcast

  • Summary

  • In this episode, we tackle some hot topics and share inspiring stories. We start with a big piece of news: the CEO of Novo Nordisk being brought before a Senate committee. This is huge because Novo Nordisk is a major player in the GLP-1 medication world, and there's a lot of scrutiny on how these drugs are priced and covered by insurance.

    We also dive into the incredible story of Leslie, who needed a combination of nutrition, exercise, GLP-1 medications, and bariatric surgery to lose an astonishing 157 pounds. Her journey is a powerful reminder that weight loss isn't a one-size-fits-all solution and often requires a multifaceted approach.

    On a different note, we discuss some eye-opening research showing that obese people tend to earn less money than their non-obese counterparts. This wage gap is especially pronounced as education levels increase, which is both shocking and troubling.

    We also get into the nitty-gritty of insurance coverage for GLP-1 medications. It's frustrating to see how many barriers there are for patients trying to get these potentially life-changing drugs. We offer some tips on how to navigate these challenges and advocate for better coverage.

    Overall, this episode is packed with important information and real-life stories that highlight the complexities of weight loss and the broader societal issues related to obesity.

    Show more Show less
activate_WEBCRO358_DT_T2

What listeners say about It Pays to be Thin

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.